Dialysis-related amyloidosis, a complication of kidney failure, is caused by the build-up of a protein called beta 2-microglobulin in the blood. This condition, which most often occurs in adults older than 60, who have been on hemodialysis for more than five years, can cause painful and stiff joints, bone cysts, torn tendons and ligaments, and can also affect the digestive tract and organs, such as the heart and lungs.
Medication therapy, newer, more effective hemodialysis filters, surgery and kidney transplant, are the available options to treat dialysis-related amyloidosis, according to the National Kidney and Urologic Diseases Information Clearinghouse.
In a first-of-its kind device, the FDA has authorized the use of Lixelle Beta 2-microglobulin Apheresis Column, manufactured by Japan-based Kaneka Corp., to treat dialysis-related amyloidosis.
The Lixelle Column contains porous cellulose beads specifically designed to bind to beta 2-microglobulin as the patient's blood passes over the beads, thereby removing the beta 2-microglobin from the blood.
The device is to be used in conjunction with hemodialysis.When the Lixelle Column is used, the blood passes through the Lixelle Column before it enters the dialysis filter, noted the FDA.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.